首页> 外文期刊>Journal of Drug Delivery >Design and Evaluation of Voriconazole Loaded Solid Lipid Nanoparticles for Ophthalmic Application
【24h】

Design and Evaluation of Voriconazole Loaded Solid Lipid Nanoparticles for Ophthalmic Application

机译:伏立康唑负载眼用固体脂质纳米粒的设计与评价

获取原文
       

摘要

Voriconazole is a second-generation antifungal agent with excellent broad spectrum of antifungal activity commercially available for oral and intravenous administration. Systemic administration of voriconazole is associated with side effects including visual and hepatic abnormalities. This study assessed the feasibility of using solid lipid nanoparticles for ocular delivery of voriconazole adopting stearic acid as lipidic material, tween 80 as a stabilizer, and Carbopol 934 as controlled release agent and for increasing the precorneal residence time in eye. The systems were prepared using two different methods, that is, ultrasonication method and microemulsion technique. The results indicated that the larger particle size of SLNs was found with microemulsion technique ( 308 ± 3.52 ?nm to 343 ± 3.51 ) compared to SLN prepared with ultrasonication method ( 234 ± 3.52 ?nm to 288 ± 4.58 ?nm). The polydispersity index values were less than 0.3 for all formulations and zeta potential of the prepared formulations by these two methods varied from ? 22.71 ± 0.63 ?mV to ? 28.86 ± 0.58 ?mV. Powder X-ray diffraction and differential scanning calorimetry indicated decrease in crystallinity of drug. The in vitro release study and the SLN formulations prepared with ultrasonication method demonstrated sustained release up to 12 hours. This study demonstrated that SLN prepared by ultrasonication method is more suitable than microemulsion technique without causing any significant effect on corneal hydration level.
机译:伏立康唑是第二代抗真菌剂,具有优异的广谱抗真菌活性,可商购用于口服和静脉内给药。伏立康唑的全身给药与包括视觉和肝异常在内的副作用有关。这项研究评估了使用固体脂质纳米粒通过硬脂酸作为脂质材料,吐温80作为稳定剂,Carbopol 934作为控释剂,并延长角膜前停留时间在眼部递送伏立康唑的可行性。使用两种不同的方法制备系统,即超声法和微乳化技术。结果表明,与超声方法制备的SLN(234±3.52μnm至288±4.58μnm)相比,微乳技术发现的SLN粒径更大(308±3.52μnm至343±3.51)。对于所有制剂,多分散指数值均小于0.3,并且通过这两种方法制得的制剂的ζ电势变化范围为α。 22.71±0.63?mV至? 28.86±0.58 µmV。粉末X射线衍射和差示扫描量热法表明药物的结晶度降低。体外释放研究和用超声方法制备的SLN制剂显示持续释放长达12小时。这项研究表明,超声法制备的SLN比微乳化技术更合适,并且对角膜水合水平没有任何显着影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号